Dr. Stryjewski is a board certified eye surgeon and life science entrepreneur.
Currently, he is Chief Scientific Officer and a Director of Pykus Therapeutics Inc. (Cambridge, MA), a company he co-founded, which develops novel biodegradable polymers for vitreoretinal applications. In addition, he continues to see patients as a surgeon with Tallman Eye Associates, a private practice in the Boston area.
Dr. Stryjewski graduated with honors from Harvard Medical School. He wrote his medical school thesis on novel therapies for proliferative vitreoretinopathy which led to his co-founding of Helio Vision Inc. (Waltham, MA), which developed a novel intravitreal formulation of methotrexate for the treatment of rare retinal diseases and received Fast Track and Orphan Drug Designations from the FDA and EMA. Helio Vision was acquired by Aldeyra Therapeutics (Lexington, MA; Nasdaq: ALDX) in 2019.
He trained in internal medicine at Massachusetts General Hospital and in ophthalmology and vitreoretinal surgery at Massachusetts Eye and Ear Infirmary, where he also served as Chief Resident, Director of the Eye Trauma Service, and was a member of the Harvard Medical School faculty. Dr. Stryjewski is the recipient of numerous awards in ophthalmology, including a Heed Fellowship and the Ronald G. Michels Fellowship Foundation Award, the nation’s highest honor for a retina surgery fellow. He has published numerous scientific papers and has been awarded several patents.
He was born in Krakow, Poland and is a naturalized American citizen. He lives with his wife and son in the Prospect Hill neighborhood of Somerville.
